EN | TR
E-ISSN: 2147-2661
Use of Bevacizumab in the Treatment of Corneal Neovascularization
PDF
Cite
Share
Request
Review
VOLUME: 45 ISSUE: 1
P: 31-36
January 2015

Use of Bevacizumab in the Treatment of Corneal Neovascularization

Turk J Ophthalmol 2015;45(1):31-36
DOI: 10.4274/tjo.85530
Tuba Çelik 1
Mustafa Köşker 2
1. Gerede Devlet Hastanesi, Göz Hastaliklari Klinigi, Bolu, Türkiye
2. Ulus Devlet Hastanesi, Göz Hastaliklari Klinigi, Ankara, Türkiye
No information available.
No information available
Received Date: 16.10.2013
Accepted Date: 30.06.2014
PDF
Cite
Share
Request

ABSTRACT

Corneal neovascularization is a serious condition resulting in various degrees of vision loss. The abnormal vascularization blocks the light depending on the corneal scarring, thus it reduces the visual acuity. Corneal neovascularization occurs as a result of shifting the balance between the angiogenic and the antiangiogenic factors on behalf of the angiogenic factors. Vascular endothelial growth factor (VEGF) is the primary mediator of angiogenesis. Anti-VEGF agents are widely used in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and the other neovascular diseases. These agents are also effective in the treatment of corneal neovascularization. Herein, we discuss the most known anti-VEGF agent bevacizumab and its administration routes, the efficiency and the complications.